Activity of rhApo2L/TRAIL and rituximab against NHL xenografts
| Cell line/treatment . | PR . | CR . |
|---|---|---|
| BJAB | ||
| Vehicle | 0/7 | 0/7 |
| rhApo2L/TRAIL | 2/7 | 0/7 |
| Rituximab | 2/7 | 0/7 |
| Combination | 1/7 | 6/7 |
| Ramos RA1 | ||
| Vehicle | 0/9 | 0/9 |
| rhApo2L/TRAIL | 0/9 | 0/9 |
| Rituximab | 0/9 | 0/9 |
| Combination | 1/9 | 7/9 |
| DoHH-2 | ||
| Vehicle | 0/10 | 0/10 |
| rhApo2L/TRAIL | 0/10 | 0/10 |
| Rituximab | 0/10 | 0/10 |
| Combination | 1/10 | 1/10 |
| SC-1 | ||
| Vehicle | 0/6 | 0/6 |
| rhApo2L/TRAIL | 0/6 | 0/6 |
| Rituximab | 1/6 | 2/6 |
| Combination | 1/6 | 2/6 |
| Cell line/treatment . | PR . | CR . |
|---|---|---|
| BJAB | ||
| Vehicle | 0/7 | 0/7 |
| rhApo2L/TRAIL | 2/7 | 0/7 |
| Rituximab | 2/7 | 0/7 |
| Combination | 1/7 | 6/7 |
| Ramos RA1 | ||
| Vehicle | 0/9 | 0/9 |
| rhApo2L/TRAIL | 0/9 | 0/9 |
| Rituximab | 0/9 | 0/9 |
| Combination | 1/9 | 7/9 |
| DoHH-2 | ||
| Vehicle | 0/10 | 0/10 |
| rhApo2L/TRAIL | 0/10 | 0/10 |
| Rituximab | 0/10 | 0/10 |
| Combination | 1/10 | 1/10 |
| SC-1 | ||
| Vehicle | 0/6 | 0/6 |
| rhApo2L/TRAIL | 0/6 | 0/6 |
| Rituximab | 1/6 | 2/6 |
| Combination | 1/6 | 2/6 |
CB17 ICR SCID mice bearing established NHL tumors (approximately 200 mm3 in size) were treated with indicated therapeutic. A partial response (PR) is defined as at least 50% tumor shrinkage and a complete response (CR) as 100% shrinkage. rhApo2L/TRAIL was administered daily for 5 consecutive days followed by a 2-day break. Rituximab was administered once a week. Both therapeutics were administered for 2 weeks. Data are number responding/number in treatment group.